Scientists find finerenone may stimulate ovarian follicles and help restore fertility in women with POI, offering a potential ...

Premature ovarian insufficiency (POI) affects 1–3% of women and has limited treatment options. Researchers report that ...

A machine learning-driven eNose detects ovarian cancer in blood plasma with 97 % sensitivity and specificity, offering a promising biomarker-agnostic approach.

HIGHLIGHTS Amplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US conferenceData showing narmafotinib activity in preclinical ...

Participants will be given a pathology request form and can have the blood test done at a convenient collection centre or at ...

Pending final negotiation, grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancerCompetitive funding award highlights Theolytics’ ...

Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ...

Allarity closes $20 mn financing to accelerate the advance of stenoparib toward US FDA approval and commercialization: Tarpon Springs, Florida Monday, March 9, 2026, 15:00 Hrs [IS ...

Young mice that received fecal transplants from older ones showed ovarian rejuvenation, suggesting potential therapeutic ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and ...

Allarity Therapeutics said on Friday it has closed a $20 million non-convertible debt financing transaction with venture capital firm Streeterville Capital. The financing is structured as a note ...

Premature ovarian insufficiency (POI) is a clinically significant cause of infertility that affects between 1 to 3% of women of childbearing age ...